CTOs on the Move

Singlera Genomics

www.singleraoncology.com

 
Singlera Genomics Inc., a fast growing company focusing on non-invasive genetic testing, was co-founded in July 2014 in San Diego, California by Professor Yuan Gao (Johns Hopkins University), Professor Kun Zhang (University of California at San Diego), Mr. Jiangli Zhang (CEO), Mr. Qiang Liu (COO), and Dr. Rui Liu (CTO). The company currently has an R&D center in La Jolla, California, and a business and clinical operation site in Shanghai, China. Singlera has proprietary technologies in single cell sequencing, DNA methylation and bioinformatics. In the past decade, Professor Gao, Professor Zhang and Dr. Liu have made outstanding achievements in their respective ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Singlera Genomics raised $20M on 08/22/2016
Singlera Genomics raised $60M on 03/27/2018
Singlera Genomics raised $150M on 12/15/2020

Similar Companies

Visionary Products Inc

Visionary Products Inc is a Draper, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cybrexa

Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. Early clinical trials of the company`s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer. As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology.

GenomeDx Biosciences

Delivering Genomic Tests that Impact Treatment Decisions GenomeDx develops and commercializes genomic tests for prostate and other urologic cancers that have a direct impact on treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs.

Zija International

Zija International is a Lindon, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OvaScience

OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining.